トップページ

ご挨拶

教室員

研究内容

研究費

研究成果

研究機器

学生の方へ

アクセス

サイトマップ

英語論文（2020年以降）
　＊2010年代の業績はこちら

1. Ishino T, Watanabe T, Tokita S, Ueda Y, Kawase K, Takano Y, Thu YM, Suzuki Y, Owa C, Inozume T, Zhou W, Nagasaki J, Kochin V, Ueno T, Kojima S, Honobe-Tabuchi A, Kawamura T, Ohnuma T, Matsuzawa T, Kawahara Y, Yamashita K, Lin J, Koseki J, Nishikawa H, Araki M, Kato N, Shimamura T, Morishita S, Suzuki Y, Mano H, Torigoe T, Kanaseki T, Kawazu M, Togashi Y*.
   Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens.
   Cell Rep, 45(1):116781, 2025.
   PMID: 41447530 DOI: 10.1016/j.celrep.2025.116781
   
   
2. Matsuoka A, Shien K, Tomida S, Ohki M, Hisamatsu K, Fujiwara R, Ishimura K, Fujii R, Higashihara T, Hayashi N, Okada K, Yoshichika R, Mukohara F, Yoshikawa M, Fukumoto Y, Suzawa K, Tomioka Y, Tanaka S, Miyoshi K, Okazaki M, Sugimoto S, Otani Y, Tanaka A, Inoue H, Togashi Y, Yamamoto H, Ennishi D, Toyooka S*.
   Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma.
   Commun Biol, 8(1):1773, 2025.
   PMID: 41402584 DOI: 10.1038/s42003-025-09162-w
   
   
3. Kanzaki H, Ishino T, Ogasawara S, Tsuchiya T, Fujiya M, Sawada M, Izai R, Akatsuka T, Miwa C, Yonemoto T, Yumita S, Nakagawa M, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Nakamura M, Kondo T, Nakamoto S, Takayashiki T, Takano Y, Takata K, Lin J, Kawazu M, Ikeda JI, Ohtsuka M, Hoshida Y, Komuta M, Togashi Y*.
   The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes.
   JHEP Rep, 7(12):101614, 2025.
   PMID: 41362708 DOI: 10.1016/j.jhepr.2025.101614
   
   
4. Nakao S, Kojima K, Sato K, Kemmotsu N, Ohuchi H, Togashi Y, Sudo Y*.
   Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3).
   J Am Chem Soc, 147(48):44131-44140, 2025.
   PMID: 41186408 DOI: 10.1021/jacs.5c13053
   
   
5. Kawase K, Kawashima S, Nishi T, Inozume T, Morinaga T, Kawazu M, Hanazawa T, Togashi Y*.
   PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy.
   Cancer Immunol Res, 13(10):1640-1654, 2025.
   PMID: 40742385 DOI: 10.1158/2326-6066.CIR-24-0853
   
   
6. Tada R, Yamaguchi T, Kanno T, Endo-Takahashi Y, Hayakawa M, Togashi Y, Yoshizawa S, Adachi Y, Negishi Y*.
   Cavitation bubble-assisted high-intensity focused ultrasound induces abscopal immune responses.
   Int Immunopharmacol, 166:115565, 2025.
   PMID: 40972334 DOI: 10.1016/j.intimp.2025.115565
   
   
7. Nishi T, Morita A, Hara N, Makimoto G, Ninomiya K, Fujii M, Rai K, Ohashi K, Hotta K, Tabata M, Togashi Y, Maeda Y, Ichihara E*.
   Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines.
   Lung Cancer, 201:108415, 2025.
   PMID: 39922174, DOI: 10.1016/j.lungcan.2025.108415
   
   
8. Naoi Y, Inukai Y, Izumikawa T, Nagasaki J, Ishino T, Ueda Y, Yin Min Thu, Fujiwara M, Baba T, Makimoto G, Suzawa K, Okada K, Yamamoto K, Sakaguchi M, Tomida S, Maeda Y, Toyooka S, Ando M, Togashi Y*.
   Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor Immunity.
   Cancer Immunol Res, In press, 2025
   PMID: 40590673 DOI: 10.1158/2326-6066.CIR-24-1144
   
   
9. Matsuura H, Ishino T, Ninomiya T, Ninomiya K, Tachibana K, Honobe-Tabuchi A, Muto Y, Inozume T, Ueda Y, Ohashi K, Maeda Y, Nagasaki J, Togashi Y*.
   High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells
   Cancer Sci, 116(5):1214-1226, 2025.
   PMID: 40017103 DOI: 10.1111/cas.70029
   
   
10. Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, Ishino T, Aki S, Lin J, Kawashima S, Nagasaki J, Ueda Y,
    Suzuki S, Makinoshima H, Itami M, Nakamura Y, Tatsumi Y, Suenaga Y, Morinaga T, Honobe-Tabuchi A, Ohnuma T,
    Kawamura T, Umeda Y, Nakamura Y, Kiniwa Y, Ichihara E, Hayashi H, Ikeda J, Hanazawa T, Toyooka S, Mano H, Suzuki T,
    Osawa T, Kawazu M, Togashi Y*.
    Immune evasion through mitochondrial transfer in the tumour microenvironment.
    Nature, 638(8049):225-236, 2025.
    PMID: 39843734, DOI: 10.1038/s41586-024-08439-0
    
    
11. Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, Ishino T, Nagasaki J, Fujiwara T, Yamamoto H,
    Hayashi H, Tachibana K, Ishida J, Otani Y, Tanaka S, Toyoda S, Okamoto I, Togashi Y.
    Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy.
    Cancer Res, 85(6):1082-1096, 2025.
    PMID: 39804971, DOI: 10.1158/0008-5472.CAN-24-2274
    
    
12. Nakajima T, Kanno T, Ueda Y, Miyako K, Endo T, Yoshida S, Yokoyama S, Asou HK, Yamada K, Ikeda K, Togashi Y, Endo Y*.
    Fatty acid metabolism constrains Th9 cell differentiation and antitumor immunity via the modulation of retinoic acid receptor signaling.
    Cell Mol Immunol, 21(11):1266-1281, 2024.
    PMID: 39187636 DOI: 10.1038/s41423-024-01209-y
    
    
13. Mukohara F, Iwata K, Ishino T, Inozume T, Nagasaki J, Ueda Y, Suzawa K, Ueno T, Ikeda H, Kawase K, Saeki Y, Kawashima S, Yamashita K, Kawahara Y, Nakamura Y, Honobe-Tabuchi A, Watanabe H, Dansako H, Kawamura T, Suzuki Y, Honda H, Mano H, Toyooka S, Kawazu M, and Togashi Y*.
    Somatic Mutations in Tumor-Infiltrating Lymphocytes Impact on Antitumor Immunity.
    Proc Natl Acad Sci USA, 121(35):e2320189121, 2024.
    PMID: 39167601 DOI: 10.1073/pnas.2320189121
    
    
14. Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N, Mizuta R, Kondo N, Takata T, Kitamatsu M, Igawa K, Fujimura A, Otani Y, Shirakawa M, Shigeyasu K, Teraishi F, Togashi Y, Suzuki M, Fujiwara T, Michiue H*.
    Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT)
    Cancer Sci, 115(10):3231-3247, 2024.
    PMID: 39119813 DOI: 10.1111/cas.16298
    
    
15. Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, Isogai E, Kawazu M, Togashi Y, Hasegawa Y, Wakabayashi Y*.
    Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model.
    Cancer Sci, 115(8):2839-2845, 2024.
    PMID: 38898727 DOI: 10.1111/cas.16246
    
    
16. Tsukada Y*, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, Kotani D, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Sato A, Nishikawa H, Ito M, Yoshino T.
    Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Br J Cancer, 131(2):283-289, 2024.
    PMID: 38834744 DOI: 10.1038/s41416-024-02730-7
    
    
17. Naoi Y, Morinaga T, Nagasaki J, Ariyasu R, Ueda Y, Yamashita K, Zhou W, Kawashima S, Kawase K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Yamasaki O, Fukushima S, Kawazu M, Suzuki Y, Nishikawa H, Hanazawa T, Ando M, Inozume T, Togashi Y*.
    CD106 in tumor-specific exhausted CD8+ T cells mediates immunosuppression by inhibiting TCR signaling.
    Cancer Res, 84(13):2109-2122, 2024.
    DOI: 10.1158/0008-5472.CAN-23-0453 PMID: 38635899
    
    
18. Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T*.
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest, 134(7):e168318, 2024.
    PMID: 38557498 DOI: 10.1172/JCI168318
    
    
19. Zhou W, Kawashima S, Ishino T, Kawase K, Ueda Y, Yamashita K, Watanabe T, Kawazu M, Dansako H, Suzuki Y, Nishikawa H, Inozume T, Nagasaki J*, Togashi Y*.
    Stem-like Progenitor and Terminally Differentiated TFH-like CD4+ T cell Exhaustion in the Tumor Microenvironment
    Cell Rep, 43(2):113797, 2024.
    DOI: 10.1016/j.celrep.2024.113797 PMID: 38363680
    
    
20. Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, Isogai E, Kawazu M, Togashi Y, Araki K, Wakabayashi Y*.
    Deletion of Pak1 in CD11c positive cells confers resistance to mouse skin carcinogenesis.
    J Invest Dermatol, 144(8):1890-1893.e5, 2024.
    DOI: 10.1016/j.jid.2024.01.021 PMID: 38325578
    
    
21. Dansako H*, Ikeda M, Ariumi Y, Togashi Y, Kato N.
    Hepatitis C virus NS5B triggers an MDA5-mediated innate immune response by producing dsRNA without the replication of viral genomes.
    FEBS J, 291(6):1119-1130, 2024
    DOI: 10.1111/febs.16980 PMID: 37863517
    
    
22. Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, Michiue H, Ichihara E, Ohashi K, Inoue T, Tamiya M, Sakai K, Ueda Y, Dansako H, Nishio K, Kiura K, Date I, Togashi Y*.
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer, 154(1):169-179, 2024.
    DOI:10.1002/ijc.34700 PMID:37611176
    
    
23. Immunological Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.
    Ikeda H, Nagasaki J, Shimizu D, Katsuya Y, Horinouchi H, Hosomi Y, Tanji E, Iwata T, Itami M, Kawazu M, Ohe Y, Suzuki T, Togashi Y*.
    JTO Clin Res Rep, 4(10):100573, 2023.
    DOI: 10.1016/j.jtocrr.2023.100573 PMID: 37799325
    
    
24. Kemmotsu N, Zhu L, Nagasaki J, Otani Y, Ueda Y, Dansako H, Fang Y, Date I, Togashi Y*.
    Combination therapy with hydrogen peroxide and irradiation promotes an abscopal effect in mouse models.
    Cancer Sci, 114(10):3848-3856, 2023.
    DOI:10.1111/cas.15911 PMID:37485636
    
    
25. Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, Araki Motoo, Togashi Y*.
    Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Cancer Sci, 114(5):1859-1870, 2023.
    DOI:10.1111/cas.15756 PMID:36762794
    
    
26. Kawase K, Kawashima S, Nagasaki J, Inozume T, Tanji E, Kawazu M, Hanazawa T, Togashi Y*.
    High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects.
    Cancer Immunol Res, 11(7):895-908, 2023
    DOI:10.1158/2326-6066.CIR-22-0815 PMID:37062030
    
    
27. Ishino T, Kawashima S, Tanji E, Ueno T, Ueda Y, Ogasawara S, Sato K, Mano H, Ishihara S, Kato N, Kawazu M*, Togashi Y*.
    Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens
    Br J Cancer ,128(6):1166-1175, 2023.
    DOI:10.1038/s41416-023-02165-6 PMID:36732592
    
    
28. Shingaki S, Koya J, Yuasa M, Saito Y, Tabata M, McClure MB, Ogawa S, Katayama K, Togashi Y, Imoto S, Kogure Y, Kataoka K*.
    Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma.
    Leukemia, 37(2):492-496, 2023.
    DOI:10.1038/s41375-022-01772-1 PMID:36522456
    
    
29. Kawashima S, Togashi Y*.
    Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Exp Dermatol. 32(3):240-249, 2023.
    DOI:10.1111/exd.14716 PMID:36437644
    
    
30. Nagasaki J, Ishino T, Togashi Y*.
    Mechanisms of resistance to immune checkpoint inhibitors.
    Cancer Sci, 113:3303-3312, 2022.
    DOI:10.1111/cas.15497 PMID:35848888
    
    
31. Nagasaki J, Togashi Y*.
    A variety of 'exhausted' T cells in the tumor microenvironment.
    Int Immunol, 34:563-570, 2022.
    DOI:10.1093/intimm/dxac013 PMID:35460561
    
    
32. Ymamoto H, Togashi Y*.
    Programmed Death-Ligand 1 Rich Premetastatic Niche in Adjuvant Chemotherapy.
    J Thorac Oncol, 17(1):10-12, 2022.
    DOI 10.1016/j.jtho.2021.10.019 : PMID:34930604
    
    
33. Ikeda H, Togashi Y*.
    Aging, cancer, and antitumor immunity.
    Int J Clin Oncol, 27:316-322, 2022.
    DOI:10.1007/s10147-021-01913-z PMID:33783658
    
    
34. Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T*.
    Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
    Clin Cancer Res, 28(6):1136-1146, 2022.
    DOI:10.1158/1078-0432.CCR-21-3213 PMID: 35063964
    
    
35. Kumagai S, Koyama S*, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H*.
    Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
    Cancer Cell, 40(2):201-218, 2022.
    DOI: 10.1016/j.ccell.2022.01.001 PMID:35090594
    
    
36. Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohkura T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa t, Kochin V, Kawamura T, Matsue H, Hino M, Mano, H, Suzuki Y, Nishikawa H, Togashi Y*.
    PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
    Cell Rep, 38(5):110331, 2022.
    DOI:10.1016/j.celrep.2022.110331 PMID:35108529
    
    
37. Kawazu M*, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Maeda Y, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H.
    HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability.
    Gastroenteology, 162(3):799-812, 2022.
    DOI:10.1053/j.gastro.2021.10.010 PMID:34687740
    
    
38. Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y*.
    Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
    Cancer Res Commun, 2(7):739-753, 2022.
    DOI: 10.1158/2767-9764.CRC-22-0050 PMID: 36923281
    
    
39. Namba S, Ueno T, Kojima S, Kobayashi K, Kawase K, Tanaka Y, Inoue S, Kishigami F, Kawashima S, Maeda N, Ogawa T, Hazama S, Togashi Y, Ando M, Shiraishi Y, Mano H, Kawazu M*.
    Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer.
    Commun Biol, 4(1):1320, 2021.
    DOI:10.1038/s42003-021-02833-4 PMID:34811492
    
    
40. Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y*.
    TIGIT/CD155 axis mediates resistance to immunotherapy in melanoma patients with the inflamed tumor microenvironment.
    J Immunother Cancer, 9(11):e003134, 2021.
    DOI: 10.1136/jitc-2021-003134 PMID:34795004
    
    
41. Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H.
    Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
    Sci Immunol, 6(65):eabc6424, 2021.
    DOI10.1126/sciimmunol.abc6424 : PMID:34767457
    
    
42. Koya J, Saito Y, Kameda T, Kogure Y, Yuasa M, Nagasaki J, McClure MB, Shingaki S, Tabata M, Tahira Y, Akizuki K, Kamiunten A, Sekine M, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Nakano N, Utsunomiya A, Togashi Y, Ogawa S, Shimoda K, Kataoka K.
    Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.
    Blood Cancer Discov, 2(5):450-467, 2021.
    DOI:10.1158/2643-3230.BCD-21-0044 PMID:34661162
    
    
43. Dansako H*, Ueda Y, Satoh S, Kato N.
    Extracellular vesicles activate ATM-Chk2 signaling pathway through the intercellular transfer of mitochondrial DNA in HBV-infected human hepatocytes.
    FASEB J, 35(6):e21680, 2021.
    DOI:10.1096/fj.202002678R PMID:34042225
    
    
44. Inamori K, Togashi Y*, Fukuoka S, Akagi K, Ogasawara K, irie T, Motooka D, Kobayashi Y, Sugiyama D, Kojima M, Shiiya N, Nakamura S, Murayama S, Suzuki Y, Ito M, Nishikawa H.
    Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
    JCI Insight, 6:137365, 2021.
    DOI:10.1172/jci.insight.137365 PMID:33755600
    
    
45. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y.
    HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
    Thorac Cancer, 12:631-642, 2021.
    
    
46. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C.
    Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.
    N Engl J Med, 384:42-50, 2021.
    
    
47. Kashima Y, Togashi Y (equally contribution), Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T.
    Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens.
    Sci Rep, 11:341, 2021.
    
    
48. Gu W, Ueda Y, Dansako H, Satoh S, Kato N.
    Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.
    FASEB BioAdv, 3(5):356-373, 2021.
    DOI:10.1096/fba.2020-00107　PMID:33977235
    
    
49. Honobe A, Sakai K, Togashi Y, Ohnura T, Kawamura T, Nishio K, Inozume T.
    Heterogeneity in congenital melanocytic nevi contributes muliticentric melanomagenesis.
    J Dermatol Sci, 100:217-219, 2020.
    
    
50. Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.
    Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    JAMA Oncol, 15:1-9, 2020.
    
    
51. Nagasaki J, Togashi Y*, Sugawara T, Itami M, Yamauchi N, Yuda J, Sugano M, Ohara Y, Minami Y, Nakamae H, Hino M, Takeuchi M, Nishikawa H.
    The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classical Hodgkin lymphoma.
    Blood Adv, 4:4069-4082, 2020.
    
    
52. Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T, Komatsu Y, Yuki S, Wakabayashi M, Nomura S, Sato A, Kuwata T, Kawazu M, Mano H, Togashi Y, Nishikawa H, Yoshino T.
    Multicenter phase　1/2　trial　of　napabucasin　and　pembrolizumab　in　patients　with　metastatic　colorectal　cancer (EPOC1503).
    Clin Cancer Res, 26:5887-5894, 2020.
    
    
53. Sato K, Mimaki S, Yamashita R, Togashi Y, Naito T, Udagawa H, Nakamura H, Katsumata S, Nakasone S, Tane K, Miyoshi T, Aokage K, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Goto K, Tsuboi M, Tssuchihara K, Ishii G.
    Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma.
    Lung Cancer, 147:12-20, 2020.
    
    
54. Kumagai S, Togashi Y (equally contribution), Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Kochin V, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K and Nishikawa H.
    The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Nat Immunol, 21:1346-1358, 2020.
    
    
55. Kumagai S, Togashi Y*, Sakai S, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata K, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H.
    An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells.
    Immunity, 53:187-203, 2020.
    
    
56. Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T.
    TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy With 5-FU Plus Cisplatin in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma.
    BMC Cancer, 20:336, 2020.
    
    
57. Sasaki A, Nakamura Y, Togashi Y (equally contribution), Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.
    Enhanced Tumor Response to Radiotherapy After PD-1 Blockade in Metastatic Gastric Cancer.
    Gastric Cancer, 23:893-903, 2020.
    
    
58. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K.
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol, 38:2053-2061, 2020.
    
    
59. Sugiyama E, Togashi Y (equally contribution), Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, Nishikawa H.
    Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer.
    Sci Immunol, 5:eaav3937, 2020.
    
    
60. Umemoto K, Togashi Y (corresponding), Arai Y, Nakamura H, Takahashi S, Tanegashima T, Kato M, Nishikawa T, Sugiyama D, Kojima M, Gotohda N, Ikeda M, Shibata T, Nishikawa H.
    The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.
    Int Immunol, 32:273-281, 2020.
    
    
61. Kato N, Ueda Y, Sejima H, Gu W, Satoh S, Dansako H, Ikeda M, Shimotohno K.
    Study of multiple genetic variations caused by persistent hepatitis C virus replication in long-term cell culture.
    Arch Virol, 165(2):331-343, 2020.
    DOI:10.1007/s00705-019-04461-0　PMID:31832864
    
    Onomura D, Satoh S, Ueda Y, Dansako H, Kato N.
    Identification of ribavirin-responsive cis-elements for GPAM suppression in the GPAM genome.
    Biochem Biophys Res Commun, 533(1):148-154, 2020.
    DOI:10.1016/j.bbrc.2020.08.112　PMID:32933750